Reactivities of HIV-1 gag-derived peptides with antibodies of HIV-1-infected and uninfected humans. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Reactivities of HIV-1 gag-derived peptides with antibodies of HIV-1-infected and uninfected humans.

AIDS Res Hum Retroviruses. 1992 Nov;8(11):1909-17. Unique Identifier : AIDSLINE MED/93144000
Haist S; Marz J; Wolf H; Modrow S; Medizinische Mikorbiologie und Hygiene, Universitat Regensburg,; Germany.

Abstract: A group of 41 peptides, each 24 amino acids long and overlapping with each other by 12 residues spanning the total gag open reading frame (orf) of HIV-1 (HTLV-IIIBH 10 isolate) were synthesized using Fmoc chemistry. The purified compounds were used in ELISA assays and tested for antibody reactivities in sera of human HIV-1-infected and noninfected individuals. Sera of HIV- humans showed reactivity against four defined regions, two in p17, one in p24, and one in p15. The values of these reactivities were elevated especially in serum samples of HIV- individuals showing cross-reaction with gag proteins on Western blot. Amino acid sequence comparison of HIV-1 gag proteins with those of human endogenous retroviruses (ERV K10, ERV 3) revealed significant similarities predominantly in the domains showing elevated antibody cross-reactions. The majority of sera from HIV-1+ individuals showed strong reactivities to the cross-reactive regions and to various other peptide sequences, a sequential epitope recognized by all HIV-1+ sera could, however, not be identified. The results suggest that human individuals may have immune reactions to endogenous retroviral protein sequences, which are enhanced by infections with HIV-1. Specific antibodies to HIV-1 gag proteins are probably mainly directed to tertiary structure defined epitopes formed by particle formation of the p24 monomers to the nucleocapsid.
Keywords: Acquired Immunodeficiency Syndrome/*IMMUNOLOGY Amino Acid Sequence Antibody Specificity Cross Reactions Gene Products, gag/*IMMUNOLOGY Human HIV Antibodies/BLOOD/*IMMUNOLOGY HIV Core Protein p24/IMMUNOLOGY HIV-1/*IMMUNOLOGY Molecular Sequence Data Peptide Fragments/CHEMICAL SYNTHESIS/*IMMUNOLOGY Sequence Homology, Amino Acid Support, Non-U.S. Gov't JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/KWDimmunologyaminoacidsequenceantibodyspecificitycrossreactionsgeneproducts,gag/KWDimmunologyhumanhivantibodies/blood/KWDimmunologyhivcoreproteinp24/immunologyhiv-1/KWDimmunologymolecularsequencedatapeptidefragments/chemicalsynthesis/KWDimmunologysequencehomology,aminoacidsupport,non-uKWDsKWDgov'tjournalarticle
930530
M9350969

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .